CIK 0001437402
- Large accelerated filer
ARDELYX, INC.
Sign in to watch- Ticker
- ARDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 510-745-7047
- Business address
- 34175 ARDENWOOD BLVD., FREMONT, CA, 94555
- Former names
- NTERYX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $486,197
- in 8 filings
Net −$486,197. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- RAAB MICHAEL −$226K President & CEO sold 3% of stake
- Bishop John E −$76K Reporting owner sold 6% of stake
- Brady James Parker −$58K Chief Human Resources Officer sold 6% of stake
- Williams Laura A −$41K Chief Patient Officer sold 3% of stake
- Foster Eric Duane −$33K Chief Commercial Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-29 | RAAB MICHAEL President & CEO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −30,000 | 670,000 | ||
| 2024-04-15 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −7,500 | $7.06 | $53K | 1,310,933 |
| 2024-04-01 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −1,518 | $7.31 | $11K | 1,318,433 |
| 2024-03-25 | Kelliher Mike | Grant or award | +160,000 | 160,000 | ||
| 2024-03-25 | Kelliher Mike | Grant or award · Stock Option (Right to Buy) | +205,000 | 205,000 | ||
| 2024-03-20 | GRAMMER ELIZABETH A | Sale 10b5-1 | −86,000 | $7.73 | $665K | 312,993 |
| 2024-03-15 | Blanks Robert | Gift | −1,000 | 367,186 | ||
| 2024-02-26 | Rosenbaum David P. Chief Development Officer | Sale | −5,183 | $9.20 | $48K | 175,936 |
| 2024-02-20 | Rosenbaum David P. Chief Development Officer | Sale | −5,017 | $8.75 | $44K | 378,985 |
| 2024-02-20 | Rosenbaum David P. Chief Development Officer | Sale | −2,294 | $8.75 | $20K | 181,119 |
| 2024-02-20 | Renz Justin A Chief Financial Officer | Sale | −5,341 | $8.75 | $47K | 304,835 |
| 2024-02-20 | RAAB MICHAEL President & CEO | Sale | −22,917 | $8.75 | $200K | 1,319,951 |
| 2024-02-20 | Blanks Robert | Sale | −5,017 | $8.75 | $44K | 368,186 |
| 2024-02-20 | GRAMMER ELIZABETH A | Sale | −4,432 | $8.75 | $39K | 398,993 |
| 2024-02-20 | Rodriguez Susan Chief Commercial Officer | Sale | −6,928 | $8.75 | $61K | 452,795 |
| 2024-02-20 | Felsch Robert Ora | Sale | −2,352 | $8.75 | $21K | 184,834 |
| 2024-02-20 | Williams Laura A Chief Medical Officer | Sale | −4,803 | $8.75 | $42K | 380,138 |
| 2024-02-08 | Rosenbaum David P. Chief Development Officer | Sale 10b5-1 | −15,344 | $9.18 | $141K | 384,002 |
| 2024-01-16 | Williams Laura A Chief Medical Officer | Grant or award | +118,750 | 384,941 | ||
| 2024-01-16 | Williams Laura A Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +152,127 | 152,127 |
Page 16 of 18 · 360 trades